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A BS TR AC T
BACKGROUND
Severe acute malnutrition contributes to 1 million deaths among children annually. 
Adding routine antibiotic agents to nutritional therapy may increase recovery rates 
and decrease mortality among children with severe acute malnutrition treated in 
the community.
METHODS
In this randomized, double-blind, placebo-controlled trial, we randomly assigned 
Malawian children, 6 to 59 months of age, with severe acute malnutrition to receive 
amoxicillin, cef di nir, or placebo for 7 days in addition to ready-to-use therapeutic 
food for the outpatient treatment of uncomplicated severe acute malnutrition. The 
primary outcomes were the rate of nutritional recovery and the mortality rate.
RESULTS
A total of 2767 children with severe acute malnutrition were enrolled. In the amox-
icillin, cef di nir, and placebo groups, 88.7%, 90.9%, and 85.1% of the children recov-
ered, respectively (relative risk of treatment failure with placebo vs. amoxicillin, 1.32; 
95% confidence interval [CI], 1.04 to 1.68; relative risk with placebo vs. cef di nir, 
1.64; 95% CI, 1.27 to 2.11). The mortality rates for the three groups were 4.8%, 
4.1%, and 7.4%, respectively (relative risk of death with placebo vs. amoxicillin, 
1.55; 95% CI, 1.07 to 2.24; relative risk with placebo vs. cef di nir, 1.80; 95% CI, 1.22 
to 2.64). Among children who recovered, the rate of weight gain was increased 
among those who received antibiotics. No interaction between type of severe acute 
malnutrition and intervention group was observed for either the rate of nutritional 
recovery or the mortality rate.
CONCLUSIONS
The addition of antibiotics to therapeutic regimens for uncomplicated severe acute 
malnutrition was associated with a significant improvement in recovery and mortal-
ity rates. (Funded by the Hickey Family Foundation and others; ClinicalTrials.gov 
number, NCT01000298.)
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T he contribution of severe acute malnutrition to the overall burden of child-hood morbidity and mortality is enor-
mous, with more than 20 million children with 
severe wasting worldwide,1 an untold number 
with kwashiorkor, and case fatality rates among 
hospitalized children that are as high as 50%.1,2 
For decades, the primary management for se-
vere acute malnutrition was based on inpatient 
rehabilitation with fortified milk formulas.3 How-
ever, international consensus guidelines now 
recommend the use of ready-to-use therapeutic 
food (RUTF) — usually a fortified spread consist-
ing of peanut paste, milk powder, oil, sugar, and 
a micronutrient supplement — in outpatient set-
tings as the preferred management for uncom-
plicated cases of severe acute malnutrition.4 De-
spite the markedly better outcomes observed with 
this revised outpatient regimen,5 10 to 15% of 
children still do not recover, even in the context 
of rigorously controlled clinical trials. Even mod-
est improvements in recovery and mortality rates 
could mean thousands of lives saved annually.
Many studies,6-15 but not all,16,17 have shown a 
high prevalence of clinically significant infections 
among children hospitalized for severe malnutri-
tion. This observation has led to treatment guide-
lines recommending the use of routine antibiotic 
agents even for children treated as outpatients,4 
although outpatients are presumably much less 
likely to have a systemic infection than are pa-
tients with complicated cases that require inpa-
tient care. This recommendation for the use of 
routine antibiotics is based on expert opinion and 
has not been directly tested in a clinical trial18; 
and observational data suggest that antibiotics are 
unnecessary and perhaps even harmful in chil-
dren with uncomplicated severe acute malnutri-
tion (i.e., children with good appetite and no 
clinical signs of sepsis).19
Most children with severe acute malnutrition 
can now be treated in rural health posts through-
out the developing world.20,21 Providing antibiotic 
therapy in addition to RUTF for all malnourished 
children in this setting would not only be com-
plex and costly but arguably unnecessary or even 
harmful.19 We conducted a prospective clinical 
trial to determine whether the routine adminis-
tration of oral antibiotics as part of the outpatient 
management of severe acute malnutrition in chil-
dren in Malawi was associated with improved 
outcomes. Rural Malawi is representative of agrar-
ian sub-Saharan Africa and populated primarily 
by subsistence farmers.22 An estimated 11% of 
the adult population in Malawi is infected with 
the human immunodeficiency virus (HIV), and 
53% of the children are stunted (height-for-age 
z score of less than –2).23
ME THODS
STUDY POPULATION AND ELIGIBILITY
We enrolled children from December 2009 through 
January 2011 at 18 feeding clinics in rural Malawi. 
Each child’s weight, length, and mid-upper-arm 
circumference were measured. Children who were 
6 to 59 months of age, with edema (indicative of 
kwashiorkor), a weight-for-height z score of less 
than −3 (indicative of marasmus),24 or both (ma-
rasmic kwashiorkor), were eligible for enrollment. 
Each eligible child was given a 30-g test feeding 
of RUTF25 under the supervision of a nurse to 
verify that the child was an appropriate candidate 
for outpatient therapy. Children who were too ill 
to consume the test dose in the clinic were hos-
pitalized for inpatient management. Detailed de-
scriptions of the study methods are provided in 
the Supplementary Appendix and the study pro-
tocol, both of which are available with the full 
text of this article at NEJM.org.
STUDY OVERSIGHT
The study was approved by ethics boards of the 
University of Malawi, Washington University in St. 
Louis, and the Malawi government. A data and 
safety monitoring board monitored adverse events 
and interim study outcomes. Caretakers of eligi-
ble children provided informed oral and written 
consent before enrollment. Antibiotics were pur-
chased at cost from the St. Louis Children’s Hos-
pital Pharmacy. RUTF was purchased at cost from 
Project Peanut Butter, which is based in Blantyre, 
Malawi. The first and last authors vouch for the 
accuracy and completeness of the data and analy-
ses reported, as well as the fidelity of the report 
to the study protocol.
STUDY DESIGN AND INTERVENTIONS
This randomized, double-blind, placebo-controlled 
clinical trial compared nutritional and mortality 
outcomes among children with uncomplicated 
severe acute malnutrition who received treatment 
as outpatients with or without antibiotics. All 
children received standardized counseling and 
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RUTF that provided approximately 175 kcal per 
kilogram of body weight per day. One group re-
ceived 80 to 90 mg of amoxicillin suspension per 
kilogram per day, divided into two daily doses; 
the second group received approximately 14 mg of 
cef di nir suspension per kilogram per day, divid-
ed into two daily doses. A suspension of 250 mg 
of amoxicillin per 5 ml was used, and the dose to 
be given to each child was based on a rounded 
amount that could be given by the field research 
pharmacist using the markings on a plastic sy-
ringe; a similar rounding of medication dose was 
used for cef di nir. The control group received pla-
cebo twice daily. Caretakers were instructed to 
administer the study drug in addition to RUTF 
during the initial 7 days of therapy.
STUDY PROCEDURES
Participants were assigned to their study group 
when caregivers drew an opaque envelope con-
taining one of nine coded letters corresponding 
to one of the three intervention groups. Caregivers 
and study personnel involved in clinical assess-
ments and data analysis were unaware of the in-
tervention assignments. Medications and placebo 
were distributed in opaque plastic bottles, with a 
plastic syringe marked with the appropriate dose 
for the child. After distribution of the study inter-
ventions, nurses instructed each caretaker in the 
use of the syringe to give the study medications 
and supervised the administration of the first 
dose in the clinic.
After enrollment and caretaker instruction, 
each child was discharged home with the as-
signed study medication and a 2-week supply of 
RUTF.25 If the household included a healthy 
child who was close in age to the participant and 
with whom the food might be shared, an extra 
allotment of RUTF was provided. Children were 
scheduled for follow-up visits at 2-week intervals, 
at which time anthropometric measurements were 
repeated; caretakers were also asked about the 
child’s interim history and adherence to the as-
signed intervention.
Children who continued to have bipedal pit-
ting edema or a weight-for-height z score below 
−2 at follow-up visits24 remained in the study 
and received nutritional counseling and another 
2-week supply of RUTF. Any child whose condition 
substantially deteriorated during the study or who 
was still malnourished after six follow-up visits 
was referred for inpatient care. Children who did 
not return for follow-up visits were visited at home 
by community health workers and a member of 
the study team. Children were considered to 
have recovered when they were without edema 
and had a weight-for-height z score of −2 or 
higher. Children who withdrew from the study, 
were still malnourished after six follow-up visits, 
were hospitalized for any reason during the 
study, or died were considered to have had treat-
ment failure.
STATISTICAL ANALYSIS
The primary end points were the nutritional recov-
ery and mortality rates in the three study groups. 
We calculated that a sample of 900 children in 
each group would provide the study with 80% 
power at an alpha level of 0.05 to detect a reduc-
tion of 4 percentage points in the rate of treat-
ment failure from an estimated baseline of 11%26 
and a reduction of 3.5 percentage points in the 
mortality rate from an estimated baseline of 8%.
In addition, one prespecified subgroup analysis 
was conducted to evaluate the interaction between 
type of severe acute malnutrition and the interven-
tion received, again with the use of recovery and 
mortality rates as the primary end points. This 
interaction was evaluated in a multiple logistic-
regression model that included baseline charac-
teristics that were significantly correlated with the 
primary outcomes in a univariate analysis.
Secondary outcomes of interest included weight 
gain, length gain, whether the antibiotics were 
associated with increased rates of adverse events, 
and time to recovery. Intention-to-treat analyses 
were used, and all tests were two-sided. Dichoto-
mous outcomes were compared with the use of 
the chi-square test and Fisher’s exact test; con-
tinuous variables were compared by means of 
Student’s t-test and analysis of variance. The 
relative-risk ratios for the outcomes in the three 
intervention groups were also computed, and 
Kaplan–Meier plots of time to recovery and time 
to death were prepared.
R ESULT S
STUDY POPULATION
A total of 3212 children with severe acute mal-
nutrition were identified from December 2009 
through January 2011; after the exclusion of in-
eligible children, the study included 2767 chil-
dren (Fig. S1 in the Supplementary Appendix). 
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Baseline characteristics of the enrolled children 
were similar among the three groups (Table 1, and 
Table S1 in the Supplementary Appendix).
STUDY INTERVENTIONS AND ADVERSE EVENTS
A total of 924 children were randomly assigned 
to the amoxicillin group, 923 to the cef di nir group, 
and 920 to the placebo group. Caregivers for 
more than 98% percent of the children reported 
that the child completed the entire 7-day course of 
the study regimen (Table S2 in the Supplementary 
Appendix).
No cases of severe allergy or anaphylaxis were 
identified. A total of three adverse events that 
were presumed to be drug reactions were report-
ed: a generalized papular rash in a child who 








Age — mo 20.6±9.7† 21.7±10.3 20.9±9.8
Mother as primary caretaker — no./total no. (%) 855/923 (92.6) 843/923 (91.3) 843/920 (91.6)
Current breast-feeding — no. (%) 444 (48.1) 399 (43.2) 431 (46.8)
Kwashiorkor — no. (%) 649 (70.2) 664 (71.9) 632 (68.7)
Marasmic kwashiorkor
No. of children (%) 78 (8.4) 73 (7.9) 93 (10.1)
Mid-upper-arm circumference — cm 10.7±1.1 10.7±0.9 10.7±1.1
Weight-for-height z score −3.75±0.64† −3.56±0.53 −3.71±0.66
Marasmus
No. of children (%) 197 (21.3) 186 (20.2) 195 (21.2)
Mid-upper-arm circumference — cm 10.9±1.1 11.0±1.1 10.9±1.1
Weight-for-height z score −3.42±0.55 −3.49±0.58 −3.44±0.59
Height-for-age z score
Mean score −3.13±1.63 −3.23±1.64 −3.21±1.47
−2 or lower — no./total no. (%) 725/917 (79.1) 756/915 (82.6) 756/910 (83.1)
−3 or lower — no./total no. (%) 490/917 (53.4) 509/915 (55.6) 504/910 (55.4)
HIV test performed — no./total no. (%)
Children tested 299/923 (32.4) 277/922 (30.0) 298/920 (32.4)
HIV-seropositive 61/298 (20.5) 60/277 (21.7) 67/296 (22.6)
HIV-seropositive and receiving ART 20/60 (33.3) 16/59 (27.1) 20/64 (31.3)
HIV-seropositive or HIV-exposed and receiving PCP  
prophylaxis
30/60 (50.0) 32/60 (53.3) 39/65 (60.0)
Mothers tested 691/922 (74.9) 687/921 (74.6) 689/917 (75.1)
HIV-seropositive 121/688 (17.6) 131/684 (19.2) 136/688 (19.8)
HIV-seropositive and receiving ART 49/117 (41.9) 59/128 (46.1) 64/129 (49.6)
Known HIV infection or exposure — no. (%) 132 (14.3) 140 (15.2) 148 (16.1)
Children with kwashiorkor 82/132 (62.1) 88/140 (62.9) 79/148 (53.4)
Children with marasmic kwashiorkor 17/132 (12.9) 21/140 (15.0) 30/148 (20.3)
Children with marasmus 33/132 (25.0) 31/140 (22.1) 39/148 (26.4)
≥1 infectious symptom in previous 2 wk — no./total no. (%) 780/924 (84.4) 772/923 (83.6) 756/920 (82.2)
Fever 580/908 (63.9) 561/915 (61.3) 569/906 (62.8)
Cough 503/917 (54.9) 470/921 (51.0) 472/915 (51.6)
Diarrhea 427/918 (46.5) 445/923 (48.2) 436/914 (47.7)
Good appetite reported — no./total no. (%) 791/913 (86.6) 775/916 (84.6) 780/912 (85.5)
* Plus–minus values are means ±SD. Baseline characteristics were similar among the groups except as noted. ART denotes 
antiretroviral therapy, HIV human immunodeficiency virus, and PCP Pneumocystis jiroveci pneumonia.
† P<0.05 for the comparison with cef di nir.
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Table 3. Secondary Outcomes, According to Intervention Group and Type of Severe Acute Malnutrition.*
Secondary Outcome Amoxicillin Cefdinir Placebo Total
Overall
Time to recovery
No. of children 820 839 783
No. of days 30±19 29±19 30±19 29±19
Weight
No. of children 883 897 873
Gain (g/kg/day)† 3.4±4.0 3.9±6.3‡ 3.1±4.1‡ 3.5±4.9
Length
No. of children 883 897 873
Gain (mm/day)§ 0.20±0.45 0.22±0.44 0.18±0.44 0.20±0.44
Mid-upper-arm circumference
No. of children 878 888 866
Gain (mm/day)§ 0.27±0.42¶ 0.28±0.42‖ 0.22±0.41¶‖ 0.26±0.42
Kwashiorkor
Time to recovery
No. of children 610 632 583
No. of days 26±16 27±18 27±17 27±17
Weight
No. of children 636 649 614
Gain (g/kg/day)† 2.7±3.4 3.2±6.7** 2.5±3.4** 2.8±4.8
Length
No. of children 636 649 614
Gain (mm/day)§ 0.21±0.48 0.24±0.47 0.20±0.48 0.22±0.48
Mid-upper-arm circumference
No. of children 633 642 609
Gain (mm/day)§ 0.26±0.45†† 0.26±0.42‡‡ 0.21±0.42††‡‡ 0.25±0.43
received amoxicillin, thrush in a child who re-
ceived cef di nir, and bloody diarrhea that resolved 
spontaneously while treatment continued in a 
child who received cef di nir. Children who re-
ceived placebo had higher rates of cough and di-
arrhea reported at the first follow-up visit than 
those who received an antibiotic agent; caretak-
ers of children who received amoxicillin reported 
cough least frequently, whereas children who 
received cef di nir had the lowest rate of reported 
diarrhea (Table S2 in the Supplementary Ap-
pendix).
NUTRITIONAL RECOVERY AND MORTALITY RATES
Overall, 88.3% of the children enrolled in the study 
recovered from severe acute malnutrition (Table 2). 
Children with marasmic kwashiorkor recovered 
less frequently and had higher mortality rates than 
children with either kwashiorkor or marasmus. 
The proportion of children who recovered was 
significantly lower among those who received 
placebo than among those who received either 
amoxicillin (3.6 percentage points lower; 95% con-
fidence interval [CI], 0.6 to 6.7) or cef di nir (5.8 per-
centage points lower; 95% CI, 2.8 to 8.7). Deaths 
accounted for the largest proportion of children 
who did not recover in each study group and for 
each type of severe acute malnutrition. The over-
all mortality rate was 5.4%, but the rate was sig-
nificantly higher among children who received 
placebo than among those who received either 
amoxicillin (relative risk, 1.55; 95% CI, 1.07 to 2.24) 
or cef di nir (relative risk, 1.80; 95% CI, 1.22 to 2.64). 
No significant differences in the causes of death, 
as reported by verbal autopsy (i.e., a structured 
investigation of events leading to the death), were 
identified among the three study groups (Table S3 
in the Supplementary Appendix). Although the 
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point estimates for nutritional recovery were high-
er and those for death were lower among children 
who received cef di nir than among those who re-
ceived amoxicillin, these differences were not sig-
nificant (P = 0.22 for recovery and P = 0.53 for death, 
for the comparison of amoxicillin and cef di nir by 
logistic regression). Recovery rates were higher and 
mortality rates were lower among children who re-
ceived antibiotics than among those who received 
placebo, across a number of baseline characteris-
tics (Fig. S2 in the Supplementary Appendix).
SECONDARY OUTCOMES
Children with marasmic kwashiorkor recovered 
significantly more slowly than children with either 
kwashiorkor or marasmus (Table 3). Kaplan–Meier 
survival analysis for all children in the study showed 
that the time to recovery was shorter in the cef di nir 
group than in the amoxicillin group or the place-
bo group and was shorter in the amoxicillin group 
than in the placebo group (Fig. 1A). Similar ly, chil-
dren who received an antibiotic agent survived 
longer than those who received placebo (Fig. 1B).
Table 3. (Continued.)
Secondary Outcome Amoxicillin Cefdinir Placebo Total
Marasmic kwashiorkor
Time to recovery
No. of children 54 51 55
No. of days 44±21 39±17 40±18 41±19
Weight
No. of children 65 67 76
Gain (g/kg/day)† 4.1±3.4 4.9±4.3 3.6±5.1 4.2±4.4
Length
No. of children 65 67 76
Gain (mm/day)§ 0.17±0.38 0.15±0.26 0.13±0.30 0.15±0.32
Mid-upper-arm circumference
No. of children 63 66 75
Gain (mm/day)§ 0.22±0.33 0.34±0.42‡‡ 0.19±0.37‡‡ 0.25±0.38
Marasmus
Time to recovery
No. of children 156 156 145
No. of days 37±23 35±21 38±23 37±22
Weight
No. of children 182 181 183
Gain (g/kg/day)† 5.6±5.3 6.0±4.7‡‡ 4.9±5.0‡‡ 5.5±5.1
Length
No. of children 182 181 183
Gain (mm/day)§ 0.15±0.33 0.21±0.35 0.16±0.32 0.17±0.34
Mid-upper-arm circumference
No. of children 182 180 182
Gain (mm/day)§ 0.32±0.37 0.34±0.41 0.28±0.38 0.31±0.39
*  Plus–minus values are means ±SD. P>0.05 for all pairwise comparisons, except as noted.
†  Weight gain was calculated from enrollment to the second follow-up visit (or to the first follow-up visit for children who 
had recovered by the time of the first follow-up visit or did not return for a second follow-up visit).
‡  P = 0.002 for the comparison of placebo with cefdinir.
§  Gains in length and mid-upper-arm circumference were calculated from enrollment until the final study visit.
¶  P = 0.01 for the comparison of placebo with amoxicillin.
‖  P = 0.002 for the comparison of placebo with cefdinir.
** P = 0.02 for the comparison of placebo with cefdinir.
†† P = 0.04 for the comparison of placebo with amoxicillin.
‡‡ P = 0.03 for the comparison of placebo with cefdinir.
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Figure 1. Kaplan–Meier Curves for Time to Nutritional Recovery and Time 
to Death.
Kaplan–Meier curves are shown for the number of study visits until nutri-
tional recovery was achieved (Panel A) or until death occurred (Panel B). 
Recovery was defined as a weight-for-height z score of −2 or higher without 
bilateral pitting edema. Follow-up visits and the distribution of ready-to-use 
therapeutic food were scheduled for every 2 weeks, but some children were 
brought early or late for their follow-up visits. All P values were calculated 
by the log-rank test.
Weight gain from enrollment until the second 
follow-up visit (or until the one follow-up visit for 
children with only one) was significantly higher 
among children who received cef di nir than among 
those who received placebo. Children who received 
either antibiotic agent also had greater increases 
in mid-upper-arm circumference than did those 
who received placebo.
BASELINE CHARACTERISTICS RELATED TO RECOVERY
As compared with children who did not recover, 
those who recovered were significantly older 
and were more likely to have their father alive 
and still in the home (Table S4 in the Supple-
mentary Appendix). Among children with ma-
rasmus or marasmic kwashiorkor, those with 
the lowest mid-upper-arm circumference and 
the lowest weight-for-height z score at enroll-
ment were most likely to have treatment failure 
or to die. Children with the lowest height-for-
age z score were least likely to recover. Although 
only 874 of 2765 children (31.6%) were tested 
for HIV, those who were known to be HIV-sero-
positive, especially if not receiving antiretrovi-
ral therapy, had the highest risks of treatment 
failure and death. Acute infectious symptoms 
and poor appetite both at enrollment and at the 
first follow-up visit (Table S5 in the Supplemen-
tary Appendix) were also associated with an in-
creased risk of treatment failure.
A multiple logistic-regression model for base-
line and intervention characteristics associated 
with nutritional recovery showed that younger age, 
marasmic kwashiorkor, greater stunting, HIV ex-
posure or infection, and a cough before enroll-
ment were associated with an increased risk of 
treatment failure (Table 4). These factors also 
proved to be significantly correlated with an in-
creased risk of death; in addition, the caretaker’s 
report of a good appetite at enrollment was sig-
nificantly correlated with a reduced risk of death. 
As with the results of the univariate analysis, re-
ceipt of amoxicillin or cef di nir was strongly cor-
related with improved outcomes, although no 
significant difference between amoxicillin and 
cef di nir was observed. The interaction term be-
tween the type of severe acute malnutrition and 
the type of intervention proved not to be sig-
nificant (P = 0.98 for nutritional recovery and 
P = 0.45 for death).
DISCUSSION
Although improvements have been made in the 
treatment of severe acute malnutrition over the 
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past decade, with the advent and widespread use 
of RUTF, more than 1 million children per year 
still die from this disease.21 Given the high inci-
dence of severe acute malnutrition worldwide,1 
the number of children who die remains unac-
ceptably high, despite the best current, proved 
treatment.27 In this double-blind, randomized, 
placebo-controlled trial, we found that the rou-
tine addition of amoxicillin or cefdinir to the out-
patient management of severe acute malnutrition 
was associated with marked improvements in re-
covery and mortality rates and significant im-
provements in weight and gain in the mid-upper-
arm circumference.
A 24.4% (95% CI, 4.1 to 40.4) reduction in the 
treatment-failure rate was observed when amox-
icillin was added to routine therapy and a 38.9% 
(95% CI, 21.1 to 52.7) reduction was observed 
with cef di nir (Table 2). Moreover, a 35.6% (95% 
CI, 6.9 to 55.4) reduction in the mortality rate was 
observed with amoxicillin, and a 44.3% (95% CI, 
18.0 to 62.2) reduction in the mortality rate was 
observed with cef di nir. Secondary outcomes (Ta-
ble 3) were also generally consistent with these 
findings, with the shortest time to recovery and 
greatest gains in weight and mid-upper-arm cir-
cumference among children who received cef di nir 
and the longest time to recovery and smallest 
gains in weight and mid-upper-arm circumfer-
ence among those who received placebo.
This study was conducted in rural sub-Saharan 
Africa in a stable subsistence farming popula-
tion with a heavy burden of food insecurity and 
HIV infection and the acquired immunodeficien-
cy syndrome, so these results may not necessar-
ily be applicable in other populations, and thus 
they warrant validation in other contexts. How-
ever, no interaction between the type of severe 
acute malnutrition and the intervention group was 
observed, suggesting that this factor alone should 
not invalidate the generalizability of these find-
ings. Although only a limited number of children 
had been tested for HIV, a high proportion of 
infected children had treatment failure or died 
(Table S4 in the Supplementary Appendix), pro-
viding further evidence for the need to provide 
integrated care for HIV infection and malnutri-
tion in such children.28,29
During this study, we pursued an aggressive 
strategy to determine the clinical status of chil-
dren lost to follow-up. Almost all the children 
whom we were able to find had in fact died or 
were so ill that they needed to be hospitalized. 
This accounts for the higher percentage of 
deaths in our study than in other studies in Ma-
lawi,26,30,31 in which the children were likely to 
have been categorized simply as having with-
drawn from the study.
The amoxicillin used in this study cost an aver-
age of $2.67 per child, and the cost of cef di nir 
was $7.85 but presumably would be lower if it 
were used on a large scale. For comparison, the 
Table 4. Variables Associated with Nutritional Recovery or Death in the Multiple Logistic-Regression Models.
Variable Nutritional Recovery Death
Odds Ratio
(95% CI) P Value
Odds Ratio
(95% CI) P Value
Age, each 1-mo increase 1.007 (1.001–1.017) 0.02 0.989 (0.981–0.998) 0.01
Kwashiorkor vs. marasmic kwashiorkor 5.88 (4.15–8.33) <0.001 0.25 (0.16–0.39) <0.001
Marasmus vs. marasmic kwashiorkor 1.74 (1.22–2.47) 0.002 0.44 (0.28–0.71) <0.001
Height-for-age z score, each 1.0-point increase 1.19 (1.09–1.31) <0.001 0.78 (0.69–0.88) <0.001
Mother or child HIV-seropositive 0.36 (0.27–0.47) <0.001 2.01 (1.36–2.95) <0.001
Cough during 2 wk before enrollment 0.76 (0.59–0.99) 0.04 1.52 (1.06–2.18) 0.02
Good appetite reported at enrollment* — — 0.51 (0.34–0.77) 0.001
Intervention group
Amoxicillin vs. placebo 1.38 (1.02–1.86) 0.03 0.67 (0.44–1.00) 0.05
Cefdinir vs. placebo 1.69 (1.24–2.31) 0.001 0.57 (0.37–0.88) 0.01
* Data for good appetite at enrollment were not significantly associated with nutritional recovery and were not included 
in the regression model.
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cost of RUTF was approximately $50 for the 
course of therapy. Caretakers reported excellent 
adherence and did not report any difficulty in 
administering the medications. Among the chil-
dren who received antibiotics, the rates of com-
mon side effects (most notably, diarrhea) were 
lower than they were among children who re-
ceived placebo (Table S2 in the Supplementary 
Appendix). One might speculate that this may sug-
gest a potential mechanism of effectiveness in the 
malnutrition armamentarium (i.e., decreasing the 
rates of bacterial pneumonia and dehydrating di-
arrhea in these immunocompromised children).
The children enrolled in this study had un-
complicated severe acute malnutrition, as do the 
vast majority of malnourished children who pres-
ent for care,21 in that they all showed a good ap-
petite at enrollment and no clinical signs of sep-
sis. The small proportion of children who did not 
meet these criteria were transferred to inpatient 
treatment. Mucosal defenses (both respiratory 
and intestinal) are known to be compromised in 
resource-limited settings such as Malawi,32 espe-
cially among malnourished children.33,34 Studies 
of bacteremia in malnourished children11 sug-
gest that most severe invasive bacterial infections 
are due to translocation across these compro-
mised mucosal surfaces. Thus, although these 
children did not specifically show signs of sepsis 
at the time of enrollment, antibiotics were effec-
tive in lowering the risk that these complications 
would develop during nutritional treatment. Al-
though the increasing threat of antimicrobial 
resistance in the developing world35-38 cannot be 
ignored and instances of highly resistant bacte-
ria have been observed in malnourished chil-
dren,39 we believe that the routine use of antibi-
otics is worth serious consideration because of 
the observed benefits of nutritional recovery and 
a reduced risk of death in this specific high-risk 
population.
Our results suggest that children with uncom-
plicated severe acute malnutrition who qualify 
for outpatient therapy4 remain at risk for severe 
bacterial infection and that the routine inclusion 
of antibiotics as part of their nutritional therapy 
is warranted. This prospective, randomized, 
double-blind, placebo-controlled study supplants 
our previous retrospective, uncontrolled study,19 
which showed no benefit of routine amoxicillin 
therapy. The results of the previous study were 
likely to have been confounded by the large dif-
ferences in baseline characteristics between the 
children who received antibiotics and those who 
did not and may also have been confounded by 
other, unidentified factors in the implementation 
of the therapeutic feeding protocols between the 
two groups. Further studies are needed to evalu-
ate long-term outcomes of routine antibiotic use 
in children with uncomplicated severe acute mal-
nutrition and to determine whether a specific high-
risk target population can be better defined.
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